Endocrine Abstracts

Introduction: Cinacalcet is an oral calcimimetic indicated in treatment of primary hyperparathyroidism in patients who are unable to undergo parathyroidectomy: do not accept surgery, there is failure of previous surgery or serious comorbidity that makes surgery impossible.Methods: Descriptive study that includes nine patients with primary hyperparathyroidism who have completed at least 48 months of treatment with cinacalcet (seven patients refusal to par...

Introduction: Familial hypocalciuric hypercalcemia (FHH) is a rare, benign, autosomal dominant condition usually caused by heterozygous inactivating mutations in the gene encoding the calcium sensing receptor (CASR).Case: 22-year-old woman referred to endocrinology for suspected polycystic ovary syndrome. Hypercalcemia is detected. Laboratory tests showed persistent hypercalcemia with a serum total calcium of 11.1 mg/dl (8.8–10.2), phosphorus 2.8, i...

Introduction: Generously supported by IPSEN)-->Prolactin (PRL) -secreting adenomas are about 40% of all pituitary adenomas. Their clinical symptoms are mainly related to development of secondary hypogonadism and/or tumor mass effects. Dopamine agonists (DA) are first-line drugs for prolactinoma patients due to their effectiveness in normalizing PRL levels and shrinking tumour mass. Surgery is an option for DA failure or tumour mass e...

Introduction and objective: Prophylactic central lymph node dissection (CLND) in patients with suspected papillary thyroid cancer (PTC) without evident lymph node metastasis (LNM), remains debatable. We propose to evaluate whether BRAF V600E mutation presence, could help to identify patients at risk for LMN.Methods: Retrospective study of patients with diagnosis of PTC, who underwent total thyroidectomy during 2002 and 2013 (n: 256) in our hospi...